Actively Recruiting
Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment
Led by Fondazione Toscana Gabriele Monasterio · Updated on 2024-09-19
961
Participants Needed
2
Research Sites
125 weeks
Total Duration
On this page
Sponsors
F
Fondazione Toscana Gabriele Monasterio
Lead Sponsor
C
CNR Institute of Clinical Physiology, Pisa, Italy
Collaborating Sponsor
AI-Summary
What this Trial Is About
Current medical treatments, in patients with stable coronary artery disease (CAD), mainly target established risk factors and are able to reduce morbidity and mortality but still leave a substantial residual risk of coronary artery disease progression and events. The main hypothesis of this study is that metabolic derangement, including pre-diabetes, elevated levels of triglycerides, low levels and functionality of high-density lipoprotein cholesterol, often associated with a chronic inflammatory state, is a currently unrecognized and undertreated conditon which could be the most relevant determinant of residual risk. The goal of HURRICANE observational study is to discover specific individual genetic/molecular profiles subtending emerging cardiometabolic and vascular risk patterns and associating with a more severe and progressive coronary artery disease. We will thus develop and preliminary validate new predictive models for the recognition of high-risk patients and explore possible new targets for individualized preventive treatment. The severity, extent and progression of coronary plaques will be assessed by qualitative and quantitative analysis of cardiac computed tomography (CCT) performed in retrospective and prospective cohorts of patients with stable coronary disease.
CONDITIONS
Official Title
Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 40 to 75 years
- Patients with known or suspected stable coronary artery disease (CAD) who underwent cardiac CT (CCT) in previous studies or are clinically referred for a first diagnostic CCT
- Fully accessible CCT image files and blood samples stored in a biobank
- Signed written informed consent
You will not qualify if you...
- Overt heart failure classified as NYHA Class III or IV and/or reduced left ventricular ejection fraction below 40%
- Serious comorbid conditions limiting expected survival to less than one year
- Cardiac CT exam of suboptimal quality
- History of previous coronary artery disease or major cardiovascular events (for prospective study participants)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fondazione Toscana Gabriele Monasterio
Pisa, Italy, Italy, 56124
Actively Recruiting
2
Irccs Synlab Sdn
Naples, Italy, 80121
Actively Recruiting
Research Team
D
Danilo Neglia, MD, PhD
CONTACT
M
Maria Sole Morelli, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here